Bionano Genomics (BNGO) Change in Accured Expenses (2017 - 2026)

Bionano Genomics has reported Change in Accured Expenses for 10 years, with the latest figure at -$1.4 million in Q1 2026.

• Quarterly Change in Accured Expenses fell 190.37% year-over-year to -$1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.5 million (up 74.42% YoY) and the FY2025 annual result came in at -$580000.0, up 74.06% from the prior year.
• Change in Accured Expenses eased to -$1.4 million in Q1 2026 per BNGO's latest filing, from $522000.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $3.5 million in Q3 2022 and troughed at -$5.3 million in Q2 2024.
• A 5-year average of -$375823.5 and a median of -$546000.0 in 2024 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2024: Change in Accured Expenses sank 1073.1% in 2022, then soared 424.54% in 2024.
• Over 5 years, Change in Accured Expenses stood at -$1.7 million in 2022, then slumped by 105.11% to -$3.5 million in 2023, then jumped by 84.35% to -$546000.0 in 2024, then surged by 195.6% to $522000.0 in 2025, then plunged by 371.46% to -$1.4 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$1.4 million, $522000.0, and $721000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.